BioCentury | Aug 4, 2018
Finance

Functions of formulation

...Endocrine/Metabolic Recombinant human α 1-antitrypsin $9 $54 $63 11% 06/06/11 ViroPharma Inc. (B) 1 Inflammation Subcutaneous Cinryze...
BioCentury | Nov 18, 2013
Strategy

Shire goes vertical

...twice-weekly infusions with the current formulation. In August, ViroPharma discontinued a Phase IIb trial evaluating subcutaneous Cinryze...
...Gene Mack and Daniel Brims valued IV Cinryze and additional indications at $33-$38 per share; subcutaneous Cinryze...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

...receiving chemotherapy Halozyme Therapeutics Inc. (NASDAQ:HALO)/ViroPharma Inc. (NASDAQ:VPHM) ViroPharma discontinues a Phase IIb trial of subcutaneous Cinryze...
BioCentury | Aug 5, 2013
Clinical News

Subcutaneous Cinryze: Phase IIb discontinued

...ViroPharma discontinued a double-blind, crossover, international Phase IIb trial evaluating subcutaneous Cinryze in combination with Halozyme's recombinant...
...The trial, which completed enrollment of 41 adolescent and adult patients, was evaluating 1,000 units subcutaneous Cinryze...
...previously anticipated for the rHuPH20 combination product. In September, FDA lifted a clinical hold for subcutaneous Cinryze...
BioCentury | Aug 5, 2013
Analyst Picks & Changes

Analyst picks & changes

...from $9 after ViroPharma Inc. (NASDAQ:VPHM) said it is discontinuing a Phase IIb trial of subcutaneous Cinryze...
...rHuPH20) from Halozyme Therapeutics Inc. (NASDAQ:HALO). The biotech discontinued a Phase IIb trial of its subcutaneous Cinryze...
BioCentury | Aug 5, 2013
Finance

Highlights of weekly biotech stock moves

...on Thursday after ViroPharma Inc. (NASDAQ:VPHM) said it is discontinuing a Phase IIb trial evaluating subcutaneous Cinryze...
BioCentury | Aug 5, 2013
Finance

Deciphering Dicerna's future

...revenues of $449M. Separately, ViroPharma announced that it is discontinuing a Phase IIb trial evaluating subcutaneous Cinryze...
BioCentury | Aug 2, 2013
Clinical News

ViroPharma discontinuing trial for subcutaneous Cinryze/rHuPH20

...on Thursday after ViroPharma Inc. (NASDAQ:VPHM) said it is discontinuing a Phase IIb trial evaluating subcutaneous Cinryze...
BioCentury | Dec 24, 2012
Clinical News

Subcutaneous Cinryze: Phase IIb started

...ViroPharm began a double-blind, crossover, international Phase IIb trial to evaluate subcutaneous Cinryze in combination with Halozyme's...
...for 8 weeks in about 40 adolescent and adult patients. Patients will receive 1,000 units subcutaneous Cinryze...
...Cinryze plus 48,000 units rHuPH20 twice weekly. In September, FDA lifted a clinical hold for subcutaneous Cinryze...
BioCentury | Oct 1, 2012
Analyst Picks & Changes

Analyst picks & changes

...his target to $40 from $29. His target reflects a higher probability of success for subcutaneous Cinryze/PH20...
Items per page:
1 - 10 of 22